HLN.L
Price:
$372.2
Market Cap:
$33.92B
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2022-07-18
Stock Exchange
LSE
Ticker
HLN.L
According to Haleon plc’s latest financial reports and current stock price. The company's current ROE is 6.54%. This represents a change of 300.32% compared to the average of 1.63% of the last 4 quarters.
The mean historical ROE of Haleon plc over the last ten years is 4.97%. The current 6.54% ROE has changed 31.60% with respect to the historical average. Over the past ten years (40 quarters), HLN.L's ROE was at its highest in in the March 2024 quarter at 2.53%. The ROE was at its lowest in in the December 2023 quarter at -0.02%.
Average
4.97%
Median
5.27%
Minimum
2.40%
Maximum
6.49%
Discovering the peaks and valleys of Haleon plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 82.90%
Maximum Annual ROE = 6.49%
Minimum Annual Increase = -2.68%
Minimum Annual ROE = 2.40%
Year | ROE | Change |
---|---|---|
2023 | 6.32% | -2.68% |
2022 | 6.49% | 23.07% |
2021 | 5.27% | 20.28% |
2020 | 4.38% | 82.90% |
The current ROE of Haleon plc (HLN.L) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
6.03%
5-year avg
4.97%
10-year avg
4.97%
Haleon plc’s ROE is less than GSK plc (18.08%), less than Reckitt Benckiser Group plc (18.70%), less than M&G plc (4.31%), less than abrdn plc (6.33%), less than Legal & General Group Plc (8.04%),
Company | ROE | Market cap |
---|---|---|
18.08% | $57.90B | |
18.70% | $34.47B | |
4.31% | $4.61B | |
6.33% | $2.36B | |
8.04% | $12.87B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Haleon plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Haleon plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Haleon plc's ROE?
How is the ROE calculated for Haleon plc (HLN.L)?
What is the highest ROE for Haleon plc (HLN.L)?
What is the 3-year average ROE for Haleon plc (HLN.L)?
What is the 5-year average ROE for Haleon plc (HLN.L)?
How does the current ROE for Haleon plc (HLN.L) compare to its historical average?